Navigation Links
Boryung and Stendhal Expand Cardiovascular Partnership in Latin America
Date:8/26/2013

Mexico City (PRWEB) August 26, 2013

Boryung Pharmaceutical Co. and Stendhal have expanded their cardiovascular partnership with a license and distribution agreement for Boryung’s Arakor Plus, an ARB combined with HTCZ for the treatment of hypertension. Stendhal will launch the product under the brand name Diarakor in 13 Latin American countries.

This agreement expands Stendhal’s cardiovascular portfolio with four additional products based on Boryung’s novel ARB Fimasartan. Stendhal will invest over $40 million in the commercialization of the Fimasartan family of products from Boryung.

Tae-hong Choi, Boryung Pharmaceutical CEO said, "We are interested in Stendhal because it is a company that shares values and a corporate culture of innovation with Boryung. This is an agreement that goes beyond economic interest since it supports a segment of the population with a major illness and whose current therapies have not resulted in a completely effective treatment."

According to Dr. Gerardo Sanchez Mejorada, Medical Director of Stendhal Mexico, "This agreement allows the companies to move closer for the benefit of the population by attacking a problem like hypertension that has been well known as a silent killer and that affects a large proportion of the population".

Boryung and Stendhal share a long-term vision focused on launching innovative cardiovascular products for the benefit of patients in Latin America. With this second license and distribution agreement between the partners, Stendhal’s Cardiovascular franchise is well-positioned to become a market leader in Latin America.

About Stendhal

Stendhal is a pharmaceutical company specialized in innovative medicine and high specialty products that offer solutions to diseases threatening human life. The company is specialized in fighting infectious diseases such as HIV/AIDS, hospital acquired infections, conditions affecting central nervous system such as Multiple Sclerosis, and Cardio Metabolic conditions like hypertension. For more information on Stendhal, please visit: http://www.stendhalpharma.com/.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11054147.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. HHS enlists Archimedes Inc. to expand governments use of health care modeling
2. Data release from the Allen Institute for Brain Science expands online atlas offerings
3. Financial Press: Bralorne Gold Mines Strikes Expands on its Ultra-High Grade Gold System in Canada
4. Mahvrick Expands to Brazil, Russia, India, China to Support Existing Client Customer Growth
5. Test-Med Joins Forces with Mollen to Expand its Service Offerings to its Customers
6. Expanding Access to Medicaid Would Save Lives: Study
7. Expanding Medicaid to low-income adults leads to improved health, fewer deaths
8. Boston University researchers expand synthetic biologys toolkit
9. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
10. Expanding database enables discoveries in emerging field of metabolomics
11. U.S. Expands SIDS Prevention Effort
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... and surrounding areas with a vital new community enrichment program, has teamed up with ... local women and children suffering from intimate abuse. To support all those victimized by ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted February 8, 2016 ... Awards. , Awards include the Information Security Executive® of the Year, ...
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... N.J. , Feb. 8, 2016  Otsuka Pharmaceutical ... announced that they have entered into a licensing agreement ... in the U.S. and Puerto Rico ... a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a new ... --> In a Phase II clinical ...
(Date:2/8/2016)... LAWRENCEVILLE, N.J. , Feb. 8, 2016   ... for healthcare professionals to guide them through GS1 Standards ... and Drug Administration (FDA) Unique Device Identification (UDI) rule. ... standards, GS1 US; Beth Gibson , senior director ... Roberts , industry development director, GS1 US ...
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
Breaking Medicine Technology: